Mycosis fungoides interferon-alfa- és PUVA-kezelése.

Translated title of the contribution: Interferon-alpha and PUVA therapy for mycosis fungoides

M. Marschalkó, J. Kovács, B. Somlai, M. Berecz, B. Hídvégi, J. Hársing, M. Désaknai, A. Horváth

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.

Original languageHungarian
Pages (from-to)2021-2023
Number of pages3
JournalOrvosi Hetilap
Volume142
Issue number37
Publication statusPublished - Sep 16 2001

Fingerprint

PUVA Therapy
Mycosis Fungoides
Interferon-alpha
Maximum Tolerated Dose
Leukopenia
Thrombocytopenia
Interferons
Fatigue
Weight Loss
Fever
Therapeutics
Recurrence
Pain
Liver
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Marschalkó, M., Kovács, J., Somlai, B., Berecz, M., Hídvégi, B., Hársing, J., ... Horváth, A. (2001). Mycosis fungoides interferon-alfa- és PUVA-kezelése. Orvosi Hetilap, 142(37), 2021-2023.

Mycosis fungoides interferon-alfa- és PUVA-kezelése. / Marschalkó, M.; Kovács, J.; Somlai, B.; Berecz, M.; Hídvégi, B.; Hársing, J.; Désaknai, M.; Horváth, A.

In: Orvosi Hetilap, Vol. 142, No. 37, 16.09.2001, p. 2021-2023.

Research output: Contribution to journalArticle

Marschalkó, M, Kovács, J, Somlai, B, Berecz, M, Hídvégi, B, Hársing, J, Désaknai, M & Horváth, A 2001, 'Mycosis fungoides interferon-alfa- és PUVA-kezelése.', Orvosi Hetilap, vol. 142, no. 37, pp. 2021-2023.
Marschalkó M, Kovács J, Somlai B, Berecz M, Hídvégi B, Hársing J et al. Mycosis fungoides interferon-alfa- és PUVA-kezelése. Orvosi Hetilap. 2001 Sep 16;142(37):2021-2023.
Marschalkó, M. ; Kovács, J. ; Somlai, B. ; Berecz, M. ; Hídvégi, B. ; Hársing, J. ; Désaknai, M. ; Horváth, A. / Mycosis fungoides interferon-alfa- és PUVA-kezelése. In: Orvosi Hetilap. 2001 ; Vol. 142, No. 37. pp. 2021-2023.
@article{ffab8d3fdfba4e8dbe71e5f7b5ba53e3,
title = "Mycosis fungoides interferon-alfa- {\'e}s PUVA-kezel{\'e}se.",
abstract = "14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.",
author = "M. Marschalk{\'o} and J. Kov{\'a}cs and B. Somlai and M. Berecz and B. H{\'i}dv{\'e}gi and J. H{\'a}rsing and M. D{\'e}saknai and A. Horv{\'a}th",
year = "2001",
month = "9",
day = "16",
language = "Hungarian",
volume = "142",
pages = "2021--2023",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "37",

}

TY - JOUR

T1 - Mycosis fungoides interferon-alfa- és PUVA-kezelése.

AU - Marschalkó, M.

AU - Kovács, J.

AU - Somlai, B.

AU - Berecz, M.

AU - Hídvégi, B.

AU - Hársing, J.

AU - Désaknai, M.

AU - Horváth, A.

PY - 2001/9/16

Y1 - 2001/9/16

N2 - 14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.

AB - 14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.

UR - http://www.scopus.com/inward/record.url?scp=0035899802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035899802&partnerID=8YFLogxK

M3 - Article

C2 - 11582733

AN - SCOPUS:0035899802

VL - 142

SP - 2021

EP - 2023

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 37

ER -